Comparative Pharmacokinetics Of Seven Bioactive Components In Normal, Sham-Operated, And Myocardial Ischemia-Reperfusion Injury Rats After Oral Administration Of The Salvia Miltiorrhiza-Moutan Cortex Herb Pair

Recently the Salvia Miltiorrhiza-Moutan Cortex (SM-MC) herb pair is considered as a promising Chinese medicinal mixture exhibiting a range of pharmacological activities, including treating cardiovascular disease due to its unique composition. In this study, we conducted the comparative pharmacokinetic analysis of seven main bioactive components of SM-MC in a different model rat. A straightforward ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) strategy that could simultaneously evaluate the levels of seven compounds was used to ensure the reliability of these pharmacokinetic analyses in rat plasma. The rat plasma samples were collected from normal, sham-operated, and myocardial ischemia-reperfusion injury (MIRI) groups at predetermined time points after the administration of SM-MC. The main pharmacokinetic parameters were detected and calculated. We successfully assessed the maximum concentration (C-max), time to C-max (T-max), the elimination rate constant (lambda(z)), total half-life (t(1/2)), total body clearance (CL), and the area under the concentration-time curve from 0 to last sampling time (AUC(0-t)) and extrapolated to infinity (AUC(0-infinity)). To sum up, an optimized UPLC-MS/MS approach that could be used to rapidly, simultaneously, and sensitively detect seven bioactive compounds derived from SM-MC extract preparations was successfully developed, which may offer a pharmacokinetic basis for preclinical and clinical studies of SM-MC herb pair for treating MIRI.